Litcius/Paper detail

DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo

Joan Tymon‐Rosario, Elena Bonazzoli, Stefania Bellone, Aránzazu Manzano, Silvia Pelligra, Adele Guglielmi, Barbara Gnutti, Nupur Nagarkatti, Burak Zeybek, Paola Manara, Luca Zammataro, Justin Harold, Dennis Mauricio, Natália Buza, Pei Hui, Gary Altwerger, Gulden Menderes, Elena Ratner, Mitchell Clark, Vaagn Andikyan, Gloria S. Huang, Dan‐Arin Silasi, Masoud Azodi, Peter E. Schwartz, Alessandro D. Santin

2021Gynecologic Oncology18 citationsDOIOpen Access PDF

Topics & Concepts

In vivoHER2/neuMedicineAntibody-drug conjugateCancer researchTrastuzumabAntibodyImmunohistochemistryEpitopeSerous fluidPertuzumabCell cultureFlow cytometryCancerMolecular biologyPathologyMonoclonal antibodyImmunologyBiologyInternal medicineBreast cancerBiotechnologyGeneticsHER2/EGFR in Cancer ResearchEndometrial and Cervical Cancer TreatmentsEstrogen and related hormone effects
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo | Litcius